Last reviewed · How we verify
AMG 301
AMG 301 is a monoclonal antibody targeting the interleukin-1 receptor type 1 (IL1R1).
AMG 301 is a monoclonal antibody targeting the interleukin-1 receptor type 1 (IL1R1). Used for Multiple myeloma.
At a glance
| Generic name | AMG 301 |
|---|---|
| Sponsor | Amgen |
| Drug class | IL-1 receptor antagonist |
| Target | IL1R1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AMG 301 works by binding to IL1R1, thereby inhibiting the interleukin-1 (IL-1) signaling pathway. This pathway plays a key role in inflammation and is implicated in various diseases, including certain types of cancer.
Approved indications
- Multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
- Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 301 CI brief — competitive landscape report
- AMG 301 updates RSS · CI watch RSS
- Amgen portfolio CI